↓ Skip to main content

Dove Medical Press

Article Metrics

Rosa damascena oil improves SSRI-induced sexual dysfunction in male patients suffering from major depressive disorders: results from a double-blind, randomized, and placebo-controlled clinical trial

Overview of attention for article published in Neuropsychiatric Disease and Treatment, March 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (93rd percentile)
  • High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

news
3 news outlets
twitter
2 tweeters
facebook
2 Facebook pages

Citations

dimensions_citation
32 Dimensions

Readers on

mendeley
69 Mendeley
Title
Rosa damascena oil improves SSRI-induced sexual dysfunction in male patients suffering from major depressive disorders: results from a double-blind, randomized, and placebo-controlled clinical trial
Published in
Neuropsychiatric Disease and Treatment, March 2015
DOI 10.2147/ndt.s78696
Pubmed ID
Authors

Serge Brand, Vahid Farnia, Jalal Shakeri, Mehdi Shirzadifar, Mansour Rezaei, Hafez Bajoghli, Edith Holsboer-Trachsler

Abstract

A substantial disadvantage of psychopharmacological treatment of major depressive disorder (MDD) with selective serotonin-reuptake inhibitors (SSRIs) is the impact on sexual dysfunction. The aim of the present study was to investigate whether the oil of Rosa damascena can have a positive influence on SSRI-induced sexual dysfunction (SSRI-I SD) of male patients who are suffering from MDD and are being treated with SSRIs. In a double-blind, randomized, and placebo-controlled clinical trial, a total of 60 male patients treated with an SSRI and suffering from MDD (mean age =32 years) and SSRI-I SD were randomly assigned to take either verum (R. damascena oil) or a placebo. Patients completed self-ratings of depression and sexual function at baseline, at 4 weeks later, and at the end of the study, 8 weeks after it started. Over time, sexual dysfunction improved more in the verum group than in the control group. Improvements were observed in the verum group from week 4 to week 8. Self-rated symptoms of depression reduced over time in both groups, but did so more so in the verum group than in the control group. This double-blind, randomized, and placebo-controlled clinical trial showed that the administration of R. damascena oil ameliorates sexual dysfunction in male patients suffering from both MDD and SSRI-I SD. Further, the symptoms of depression reduced as sexual dysfunction improved.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 69 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 1%
Unknown 68 99%

Demographic breakdown

Readers by professional status Count As %
Student > Master 12 17%
Student > Ph. D. Student 9 13%
Student > Bachelor 9 13%
Researcher 7 10%
Student > Doctoral Student 4 6%
Other 12 17%
Unknown 16 23%
Readers by discipline Count As %
Medicine and Dentistry 14 20%
Psychology 10 14%
Agricultural and Biological Sciences 9 13%
Pharmacology, Toxicology and Pharmaceutical Science 5 7%
Biochemistry, Genetics and Molecular Biology 4 6%
Other 10 14%
Unknown 17 25%

Attention Score in Context

This research output has an Altmetric Attention Score of 26. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 February 2022.
All research outputs
#1,258,671
of 22,797,621 outputs
Outputs from Neuropsychiatric Disease and Treatment
#162
of 2,984 outputs
Outputs of similar age
#17,193
of 256,531 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#10
of 67 outputs
Altmetric has tracked 22,797,621 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,984 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.6. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 256,531 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 67 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.